Table 4 Frequency of intrathecal IgM and IgA synthesis, IgM and IgA CSF/serum ratios, intrathecal IgM and IgA fractions, amount of locally produced IgM and IgA, and absolute IgM and IgA concentrations in the CSF and serum in group I
Units | Total | ≤ 14 d | > 14 d | Acute B/SC subgroup | Acute PN/CN/H subgroup | |
|---|---|---|---|---|---|---|
Intrathecal IgA synthesis | ||||||
QIgA > Qlim(IgA) | Samples | 1/101 (1%) | 0/72 (0%) | 1/19 (5%) | 0/59 (0%) | 0/12 (0%) |
QIgA, all LPs | – | 2.1 (0.4–17.6;101) | 2.1 (0.6–17.6;72) | 2.4 (0.7–6.6;19) | 2.19 (0.56–17.6;59) | 1.78 (0.69–7;12) |
QIgA, if positive | – | 6.6 (6.6–6.6;1) | n.a. (n.a.;0) | 6.6 (6.6–6.6;1) | n.a. (n.a.;0) | n.a. (n.a.;0) |
IgA-IF, all LPs | % IgA(CSF) | 0 (0–3.2;101) | 0 (0–0;72) | 0 (0–3.2;19) | 0 (0–0;59) | 0 (0–0;12) |
IgA-IF, QIgA positives | % IgA(CSF) | 3.2 (3.2–3.2;1) | n.a. (n.a.;0) | 3.2 (3.2–3.2;1) | n.a. (n.a.;0) | n.a. (n.a.;0) |
IgA-IF, > 10% | Samples | 0/101 (0%) | 0/72 (0%) | 0/19 (0%) | 0/59 (0%) | 0/12 (0%) |
IgA-loc, all LPs | mg/l | 0 (0–0.8;101) | 0 (0–0;72) | 0 (0–0.8;19) | 0 (0–0;59) | 0 (0–0;12) |
IgA-loc, QIgA positives | mg/l | 0.8 (0.8–0.8;1) | n.a. (n.a.;0) | 0.8 (0.8–0.8;1) | n.a. (n.a.;0) | n.a. (n.a.;0) |
IgA CSF | mg/l | 6.04 (0.9–56.3;101) | 6.38 (1.02–56.3;72) | 7.01 (1–26.1;19) | 7.01 (1.29–56.3;59) | 5.22 (1.02–28.5;12) |
IgA serum | g/l | 3.11 (0.87–7.29;106) | 3.1 (0.87–7.29;72) | 3.16 (0.9–6.5;20) | 3.1 (0.87–7.29;59) | 2.89 (1–6.14;12) |
IgA serum, elevated | Samples | 31/106 (29%) | 20/72 (27.8%) | 7/20 (35%) | 16/59 (27%) | 4/12 (33%) |
Intrathecal IgM synthesis | ||||||
QIgM > Qlim(IgM) | Samples | 4/100 (4%) | 2/72 (3%) | 0/19 (0%) | 2/58 (3%) | 0/13 (0%) |
QIgM, all LPs | – | 0.5 (0.1–20.2;100) | 0.5 (0.1–20.2;72) | 0.4 (0.1–1.6;19) | 0.56 (0.11–20.2;58) | 0.5 (0.16–4.96;13) |
QIgM, if positive | – | 4.2 (1–20.2;4) | 12.6 (4.9–20.2;2) | n.a | 12.56 (4.9–20.2;2) | n.a. (n.a.;0) |
IgM-IF, all LPs | % IgM(CSF) | 0 (0–49.2;100) | 0 (0–12.1;72) | 0 (0–0;19) | 0 (0–12.1;58) | 0 (0–0;13) |
IgM-IF, QIgM positives | % IgM(CSF) | 21.7 (11.6–49.2;4) | 11.8 (11.6–12.1;2) | n.a. (n.a.;0) | 11.8 (11.6–12.1;2) | n.a. (n.a.;0) |
IgM-IF, > 10% | Samples | 4/100 (4%) | 2/72 (2.8%) | 0/19 (0%) | 2/58 (3.4%) | 0/13 (0%) |
IgM-loc, all LPs | mg/l | 0 (0–2.1;100) | 0 (0–2.1;72) | 0 (0–0;19) | 0 (0–2.1;58) | 0 (0–0;13) |
IgM-loc, QIgM positives | mg/l | 0.88 (0.46–2.11;4) | 1.32 (0.53–2.11;2) | n.a | 1.3 (0.5–2.1;2) | n.a. (n.a.;0) |
IgM CSF | mg/l | 0.49 (0.1–18.2;100) | 0.5 (0.1–18.2;72) | 0.49 (0.2–2.54;19) | 0.5 (0.14–18.2;58) | 0.44 (0.1–6.2;13) |
IgM serum | g/l | 0.86 (0.04–3.98;106) | 0.9 (0.1–3.98;73) | 0.81 (0.31–2.1;19) | 0.9 (0.1–3.98;59) | 0.9 (0.5–2.51;13) |
IgM serum, elevated | Samples | 6/106 (6%) | 5/73 (6.8%) | 0/19 (0%) | 4/59 (7%) | 1/13 (8%) |